Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

Inclusion Criteria

Patients may be eligible for this study if they:

• Are at least 18 years old.
• Have a chronic (long-term) HIV infection (greater than 90 days) or a recent HIV infection.
• Have a plasma viral load (level of HIV in the blood) of at least 5,000 copies/ml (for chronically infected patients only).
• Are able to follow study requirements.
• Agree to practice reliable forms of birth control such as barrier or surgical methods, starting 1 month prior to entry and while enrolled in the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have had prior anti-HIV treatment (for recently infected patients only).
• Have a history of blood-clotting problems.
• Have ever received treatment with protease inhibitors or 3TC.
• Are at high risk for developing an infection in the heart.
• Are critically ill.
• Are mentally disabled, a prisoner, or confined in an institution.
• Are breast-feeding or pregnant.
• Have gastrointestinal problems that might interfere with drug absorption or are unable to take medicines by mouth.
• Need regular blood transfusions.
• Have had an unexplained fever higher than 38.5 C for more than 14 days within 30 days of enrollment.
• Have an opportunistic (AIDS-related) infection that requires treatment (treatment must be completed 30 days before the start of the study).
• Are taking certain medications that may interfere with the study.